Financial Consulate’s Bio-Rad Laboratories Class A BIO Stock Holding History

Financial Consulate’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.78K	Buy	+10	New	+$3.49K	﹤0.01%	962

Other funds holding BIO

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Hosking Partners London, United Kingdom $2.81B AUM 67.07% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $175M AUM 28.78% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return

Focused Alpha LLC Denver, Colorado $402M AUM 23.92% 1-Year Est. Return

Financial Consulate's BIO Position: Q3 2026 in Review

Financial Consulate opened a new position in Bio-Rad Laboratories Class A (BIO) in Q3 2026: 10 shares worth $3.78K. The stake represents ﹤0.01% of the portfolio and ranks #962 among its holdings.

69 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

Financial Consulate held 10 shares of Bio-Rad Laboratories Class A worth $3.78K as of Q3 2026.
Bio-Rad Laboratories Class A was a new Financial Consulate position in Q3 2026.
Bio-Rad Laboratories Class A made up ﹤0.01% of Financial Consulate's portfolio in Q3 2026, its #962 holding.
69 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on Financial Consulate's 13F filing for Q3 2026, filed 23 Oct 2026.